- Company
- Krazati receives orphan drug designation in Korea
- by Eo, Yun-Ho Jan 9, 2025 05:56am
- The second KRAS inhibitor 'Krazati' has been designated as an orphan drug in Korea. The Ministry of Food and Drug Safety (MFDS) recently announced the news through the first orphan drug designation announcement of the new year. Specifically, Krazati is indicated for 'locally advanced or metastatic non-small cell lung cancer (NSCLC) wit
- Company
- Wegovy vs Mounjaro in KOR…who's the winner?
- by Moon, sung-ho Jan 9, 2025 05:56am
- As more people are living with obesity in the world, obesity treatment is gaining popularity. According to the World Obesity Federation report, more than half of the world's population in 2035, 10 years from now, will be categorized as overweight or obese. South Korea is projected to have a similar rate. At the end of last year, Novo Nordisk'
- Company
- Sales of Flu drug Tamiflu did not fare so well last year
- by Nho, Byung Chul Jan 8, 2025 05:53am
- The oseltamivir-based flu treatment market, commonly represented by Tamiflu, is on a vertical decline after peaking in sales in 2023. The market for related preparations was valued at KRW 35.6 billion in 2023, the largest in 5 years. By 3Q 2024, the oseltamivir market posted sales of KRW 6.2 billion; even when the sales of the fourth q
- Company
- J.P. Morgan selects ADC and obesity as big deal keywords
- by Moon, sung-ho Jan 8, 2025 05:53am
- With the opening of the 'J.P. Morgan Healthcare Conference', which attracted much attention last year with domestic pharmaceutical and biotech companies announcing the achievement of 'big deals,’ approaching, attention is gathering on what results will be announced this year. The keywords of this year's event are glucagon-like peptide-1 (GLP
- Company
- Expansion of NIP needed for 20-valent pneumococcal vaccine
- by Whang, byung-woo Jan 8, 2025 05:53am
- "Invasive pneumococcal disease remains the most common invasive infection and poses a significant burden. Pneumococcal diseases, such as pneumonia or ear infection, pose significant burden. The new vaccine must cover conventional serotypes as well as newly introduced serotypes to manage the invasive pneumococcal infection and expect an additiona
- Company
- New drug 'Truqap' for HER2- breast cancer Rx available
- by Son, Hyung Min Jan 8, 2025 05:53am
- 'Truqap,' an oral anticancer drug that targets AKT gene mutation, is now available for prescription at general hospitals. According to industry sources, AstraZeneca Korea's Truqap (capivasertib), a treatment for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, has passed t
- Company
- Twice yearly HIV drug 'lenacapavir' receives ODD
- by Eo, Yun-Ho Jan 7, 2025 06:05am
- Twice yearly injectable 'lenacapavir' for HIV prevention has been designated as an orphan drug in South Korea. The Ministry of Food and Drug Safety (MFDS) recently announced this through the new year's first orphan drug designation notification. The drug is indicated 'In combination with other antiretroviral therapy, for treatment of p
- Company
- AstraZeneca Korea recertified Innovative Pharma Company
- by Whang, byung-woo Jan 7, 2025 06:05am
- AstraZeneca Korea announced today that it has successfully extended its certification as a 2024 Innovative Pharmaceutical Company by the Ministry of Health and Welfare. This marks the third consecutive recertification since the company was first certified in 2018, and recognizes the company's steady R&D investments and achievements made t
- Company
- 1st RSV preventive inj 'Beyfortus' can be prescribed
- by Eo, Yun-Ho Jan 6, 2025 05:56am
- The first injectable antibody drug approved in South Korea to prevent respiratory syncytial virus (RSV), 'Beyfortus,' is now available for prescription at general hospitals. According to industry sources, Sanofi Korea's Beyfortus (nirsevimab) has passed the drug committees (DC) of medical centers, including Seoul National University Hospi
- Company
- Balversa may be prescribed at general hospitals in Korea
- by Eo, Yun-Ho Jan 6, 2025 05:56am
- The new bladder cancer drug Balversa may now be prescribed in Korea’s Big 5 tertiary hospitals in Korea. According to industry sources, Janssen Korea's FGFR-inhibiting urothelial carcinoma (bladder cancer) drug Balversa (erdafitinib) recently passed the drug committees (DCs) of tertiary hospitals including Samsung Medical Center, Seoul Na
